Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide (TARMIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02805725
Recruitment Status : Active, not recruiting
First Posted : June 20, 2016
Last Update Posted : February 7, 2020
Sponsor:
Collaborator:
PharmaMar
Information provided by (Responsible Party):
Institut Bergonié

Brief Summary:
Assessment of the efficacy and safety of trabectedin and metronomic cyclophosphamide (CP) in patients with advanced pretreated soft-tissue sarcomas, once the Maximum Tolerated Dose (MTD) have been determined (phase I trial).

Condition or disease Intervention/treatment Phase
Soft-tissue Sarcomas Drug: Phase 1: Trabectedin Drug: Phase 2: Trabectedin Drug: Phase 1: Cyclophosphamide Drug: Phase 2: Cyclophosphamide Phase 1 Phase 2

Detailed Description:
Phase I: Multicenter Phase I trial based on a dose escalation study design (3+3 traditional design). Phase II: One-arm, multicenter Phase II trial based on two-stage optimal Simon's design.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 71 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide (CP) in Patients With Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II Study From the French Sarcoma Group.
Actual Study Start Date : December 2015
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Phase 1: Trabectedin + Cyclophosphamide
Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule. Trabectedin will be administered intravenously, 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks.
Drug: Phase 1: Trabectedin

A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Patients will be allocated 4 doses of Trabectedin following a 3 + 3 design:


Drug: Phase 1: Cyclophosphamide
A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.

Experimental: Phase 2: Trabectedin + Cyclophosphamide
Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule. Trabectedin will be administered intravenously, 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks.
Drug: Phase 2: Trabectedin
All patients will be treated at the RP2D of trabectedin defined in the preliminary phase I trial with the same schedule as in the phase I trial.

Drug: Phase 2: Cyclophosphamide
All patients will be treated with metronomic cyclophosphamide with the same schedule as in the phase I trial.




Primary Outcome Measures :
  1. Phase I: Maximum tolerated dose (MTD) evaluated on the first cycle (D1 to D28) of Trabectedin when administered in association with CP [ Time Frame: During the first cycle (28 days) ]
  2. Phase II: Assessment of the antitumor activity of the association of Trabectedin and metronomic cyclophosphamide based on 6 month non-progression (CR, PR or SD more than 24 weeks) following RECIST v1.1 criteria [ Time Frame: Phase II: 6 months after the beginning of treatment ]

Secondary Outcome Measures :
  1. Recommended phase II dose (RP2D) of Trabectedin when administered in association with CP [ Time Frame: Throughout the treatment period, an average of 6 months ]
  2. Dose Limiting Toxicities (DLT) of Trabectedin when administered in association with CP [ Time Frame: During the first cycle (28 days)] ]
  3. Phase I: Antitumor activity of Trabectedin when administered in association with CP in terms of objective response rate (ORR) as per RECIST V1.1 [ Time Frame: Throughout the treatment period, an average of 6 months ]
  4. Phase I: Antitumor activity of Trabectedin when administered in association with CP in terms of 6-month Non-progression rate (NPR) as per RECIST 1.1 [ Time Frame: 6-month Non-progression rate (NPR) as per RECIST ]
  5. Phase I: Antitumor activity of Trabectedin when administered in association with CP in terms of 1-year Progression-free survival (PFS) as per RECIST 1.1 [ Time Frame: 1-year Progression-free survival (PFS) ]
  6. Phase I: Antitumor activity of Trabectedin when administered in association with CP in terms of 1-year Overall Survival (OS) [ Time Frame: 1-year Overall Survival (OS) as per RECIST ]
  7. Phase I: PK measurements expressed as Area Under Curve for CP [ Time Frame: Day 1 of cycle1, Day 15 of cycle1(Each cycle is 28 days)] ]
  8. Phase I: PK measurements expressed as Area Under Curve for Trabectedin [ Time Frame: Day 1 of cycle1, Day 15 of cycle1(Each cycle is 28 days)] ]
  9. Phase I: PK measurements expressed as half-life for CP [ Time Frame: Day 1 of cycle1, Day 15 of cycle1(Each cycle is 28 days)] ]
  10. Phase I: PK measurements expressed as half-life for Trabectedin [ Time Frame: Day 1 of cycle1, Day 15 of cycle1(Each cycle is 28 days) ]
  11. Phase I: PK measurements expressed as concentration peak for CP [ Time Frame: Day 1 of cycle1, Day 15 of cycle1(Each cycle is 28 days) ]
  12. Phase I: PK measurements expressed as concentration peak for Trabectedin [ Time Frame: Day 1 of cycle1, Day 15 of cycle1(Each cycle is 28 days) ]
  13. Phase I: Predictive biomarkers analysis (cytokines levels) [ Time Frame: Day 1 cycle 1 and Day 1 cycle 2 (Each cycle is 28 days) ]
  14. Phase I: Predictive biomarkers analysis (VEGF and TPS-1 levels) [ Time Frame: Day 1 cycle 1 and Day 1 cycle 2 (Each cycle is 28 days) ]
  15. Phase I: Predictive biomarkers analysis (lymphocytes levels) [ Time Frame: Day 1 cycle 1 and Day 1 cycle 2 (Each cycle is 28 days) ]
  16. Phase I: Number of participants with exploratory markers available (markers analyzed for Hematoxylin and eosin staining (H&E)) [ Time Frame: before treatment initiation and Day 28 cycle 1 ]
  17. Phase I: Number of participants with exploratory markers available (markers analyzed for Immunohistochemistry (IHC) [ Time Frame: before treatment initiation and Day 28 cycle 1 ]
  18. Phase II: Antitumor activity of Trabectedin when administered in association with CP in terms of objective response rate (ORR) as per RECIST V1.1 [ Time Frame: Throughout the treatment period, an average of 6 months ]
  19. Phase II: Antitumor activity of Trabectedin when administered in association with CP in terms of 1-year Progression-free survival (PFS) as per RECIST V1.1 [ Time Frame: 1-year Progression-free survival (PFS) as per RECIST ]
  20. Phase II: Antitumor activity of Trabectedin when administered in association with CP in terms of 1-year Overall Survival (OS) [ Time Frame: 1-year Overall Survival (OS) ]
  21. Phase II: Toxicity graded using the common toxicity criteria from the NCI v4.0 [ Time Frame: Throughout the treatment period, an average of 6 months ]
  22. Phase II (optional): Predictive biomarkers analysis (cytokines levels) [ Time Frame: Day 1 cycle 1 and Day 1 cycle 2 (Each cycle is 28 days) ]
  23. Phase II (optional): Predictive biomarkers analysis (VEGF and TPS-1 levels) [ Time Frame: Day 1 cycle 1 and Day 1 cycle 2 (Each cycle is 28 days) ]
  24. Phase II (optional): Predictive biomarkers analysis (lymphocyte levels [ Time Frame: Day 1 cycle 1 and Day 1 cycle 2 (Each cycle is 28 days) ]
  25. 27. Phase II (optional): Number of participants with exploratory markers available (markers analyzed for Hematoxylin and eosin staining (H&E)) [ Time Frame: before treatment initiation and Day 28 cycle 1 ]
  26. 28. Phase II (optional): Number of participants with exploratory markers available (markers analyzed for Immunohistochemistry (IHC) [ Time Frame: before treatment initiation and Day 28 cycle 1 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with soft-tissue sarcoma histologically confirmed by central review
  2. Metastatic or unresectable locally advanced disease,
  3. Age ≥ 18 years,
  4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2,
  5. Life expectancy > 3 months,
  6. Measurable disease according to RECIST v1.1 outside any previously irradiated field,
  7. For patients included in phase II study, progressive disease according to RECIST v1.1 criteria diagnosed on the basis of two CT scan or MRI obtained at an interval less than 6 months in the period of 12 months prior to inclusion and confirmed by central review,
  8. Previous use of Anthracyclines,
  9. Have provided tissue from an archival tissue sample,
  10. At least three weeks since last chemotherapy, immunotherapy or any other pharmacological treatment and/or radiotherapy,
  11. Adequate hematological, renal, metabolic and hepatic function:

    1. Hemoglobin ≥ 9 g/dl (patients may have received prior red blood cell [RBC] transfusion, if clinically indicated); absolute neutrophil count (ANC) ≥ 1.5 x 10^9/l, and platelet count ≥ 100 x 10^9/l
    2. Alanine aminotransferase (ALT), aspartate aminotransferase (AST)< or = 2.5 x upper limit of normality (ULN) ( < or = 5 in case of extensive liver involvement) and alkaline phosphatase (AP) < or = 2.5 x ULN
    3. Total bilirubin < or = ULN.
    4. Albumin ≥ 25 g/l
    5. Serum Creatinine < or =1.5 x ULN or calculated creatinine clearance (CrCl) ≥ 30 ml/min (according to Cockroft formula).
    6. Creatine Phosphokinase (CPK) < or = 2.5 x ULN
  12. Women of childbearing potential must have a negative serum pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for six months after discontinuation of treatment. Acceptable methods of contraception include intrauterine device (IUD), oral contraceptive, subdermal implant and double barrier,
  13. No prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma,
  14. Recovery to grade ≤ 1 from any adverse event (AE) derived from previous treatment (excluding alopecia of any grade and non-painful peripheral neuropathy grade ≤ 2) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 4.0),
  15. Patients with a French social security in compliance with the Law relating to biomedical research (Article 1121-11 of French Public Health Code),
  16. Voluntarily signed and dated written informed consent prior to any study specific procedure.

Exclusion Criteria:

  1. Previous treatment with Trabectedin,
  2. Currently active bacterial or fungus infection (> grade 2 CTC [CTCAE] HIV1, HIV2, hepatitis B or hepatitis C infections,
  3. History of chronic alcohol use and/or cirrhosis,
  4. The following unstable cardiac conditions are not allowed:

    • Congestive heart failure
    • Angina pectoris
    • Myocardial infarction within 1 year before registration
    • Uncontrolled arterial hypertension defined as blood pressure ≥ 150/100 mmHg despite optimal medical therapy
    • Arrhythmias clinically significant
  5. Patients unable to receive corticotherapy,
  6. Known central nervous system malignancy (CNS),
  7. Men or women of childbearing potential who are not using an effective method of contraception as previously described; women who are pregnant or breast feeding,
  8. Participation to a study involving a medical or therapeutic intervention in the last 30 days,
  9. Previous enrolment in the present study,
  10. Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons,
  11. Known hypersensitivity to any involved study drug or any of its formulation components.
  12. Recent vaccination (in the last 2 weeks before inclusion) for yellow fever.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02805725


Locations
Layout table for location information
France
Institut Bergonié
Bordeaux, France, 33076
Sponsors and Collaborators
Institut Bergonié
PharmaMar
Layout table for additonal information
Responsible Party: Institut Bergonié
ClinicalTrials.gov Identifier: NCT02805725    
Other Study ID Numbers: IB 2015-04
First Posted: June 20, 2016    Key Record Dates
Last Update Posted: February 7, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Institut Bergonié:
Advanced solid tumor
Advanced pretreated soft tissue sarcomas
Phase I/II trial
Dose escalation
PK study
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Cyclophosphamide
Trabectedin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists